AR027358A1 - Proteinas que producen una alteracion en la respuesta inmunogenica y metodos para fabricarlas y utilizarlas - Google Patents
Proteinas que producen una alteracion en la respuesta inmunogenica y metodos para fabricarlas y utilizarlasInfo
- Publication number
- AR027358A1 AR027358A1 ARP010100505A ARP010100505A AR027358A1 AR 027358 A1 AR027358 A1 AR 027358A1 AR P010100505 A ARP010100505 A AR P010100505A AR P010100505 A ARP010100505 A AR P010100505A AR 027358 A1 AR027358 A1 AR 027358A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- protease
- variant
- proteins
- reduce
- Prior art date
Links
- 230000009851 immunogenic response Effects 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 230000004075 alteration Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 108091005804 Peptidases Proteins 0.000 abstract 6
- 239000004365 Protease Substances 0.000 abstract 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 239000000443 aerosol Substances 0.000 abstract 2
- 239000000428 dust Substances 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000000047 product Substances 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000002009 allergenic effect Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000004140 cleaning Methods 0.000 abstract 1
- 239000003344 environmental pollutant Substances 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 231100000719 pollutant Toxicity 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 239000004753 textile Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/500,135 US6838269B1 (en) | 1998-04-15 | 2000-02-08 | Proteins producing an altered immunogenic response and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR027358A1 true AR027358A1 (es) | 2003-03-26 |
Family
ID=23988185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100505A AR027358A1 (es) | 2000-02-08 | 2001-02-02 | Proteinas que producen una alteracion en la respuesta inmunogenica y metodos para fabricarlas y utilizarlas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6838269B1 (https=) |
| EP (1) | EP1254240B1 (https=) |
| JP (1) | JP5112587B2 (https=) |
| KR (1) | KR20020073582A (https=) |
| CN (3) | CN1418253A (https=) |
| AR (1) | AR027358A1 (https=) |
| AT (1) | ATE355377T1 (https=) |
| AU (1) | AU3651201A (https=) |
| CA (1) | CA2399019A1 (https=) |
| DE (1) | DE60126915T2 (https=) |
| DK (1) | DK1254240T3 (https=) |
| WO (1) | WO2001059130A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967080B1 (en) * | 1990-12-05 | 2005-11-22 | Novozymes A/S | Proteins with changed epitopes and methods for the production thereof |
| US6936249B1 (en) * | 1998-04-15 | 2005-08-30 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
| CA2249648A1 (en) * | 1998-11-04 | 2000-05-04 | Nabil G. Seidah | Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity |
| HUP0402071A2 (hu) * | 2001-02-06 | 2005-01-28 | Merck Patent Gmbh. | Csökkentett immunogenitású, módosított leptin |
| JP2005514026A (ja) * | 2001-12-31 | 2005-05-19 | ジェネンコー・インターナショナル・インク | 免疫反応の変化を生じるプロテアーゼ、ならびにその製造および利用方法 |
| MXPA04006811A (es) * | 2002-01-16 | 2004-10-11 | Genencor Int | Variantes de proteasa substituidas con multiplos. |
| US20050239043A1 (en) * | 2002-02-26 | 2005-10-27 | Harding Fiona A | Subtilisin carlsberg proteins with reduced immunogenicity |
| WO2004003186A2 (en) * | 2002-06-26 | 2004-01-08 | Novozymes A/S | Subtilases and subtilase variants having altered immunogenicity |
| EP2500423B1 (en) * | 2003-02-26 | 2015-06-17 | Danisco US Inc. | Amylases producing an altered immunogenic response and methods of making and using the same |
| EP1597363B1 (en) * | 2003-02-26 | 2015-07-15 | Danisco US Inc. | Amylases producing an altered immunogenic response and methods of making and using the same |
| PT1861120T (pt) | 2005-03-23 | 2016-08-18 | Glaxosmithkline Biologicals Sa | Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória |
| AU2006236905B2 (en) * | 2005-04-15 | 2010-06-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| HRP20140488T1 (hr) | 2006-07-17 | 2014-07-04 | Glaxosmithkline Biologicals S.A. | Cjepivo protiv influence |
| JP5230397B2 (ja) * | 2008-12-18 | 2013-07-10 | 独立行政法人科学技術振興機構 | 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法 |
| ES2594893T3 (es) | 2009-12-16 | 2016-12-23 | Abbvie Biotherapeutics Inc. | Anticuerpos anti HER2 y sus usos |
| CN106661566A (zh) | 2014-07-04 | 2017-05-10 | 诺维信公司 | 枯草杆菌酶变体以及编码它们的多核苷酸 |
| EP3739029A1 (en) | 2014-07-04 | 2020-11-18 | Novozymes A/S | Subtilase variants and polynucleotides encoding same |
| CN109715792A (zh) * | 2016-06-03 | 2019-05-03 | 诺维信公司 | 枯草杆菌酶变体和对其进行编码的多核苷酸 |
| WO2026024921A1 (en) * | 2024-07-25 | 2026-01-29 | The Procter & Gamble Company | Detergent composition comprising a subtilisin variant and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2926808A1 (de) | 1978-07-04 | 1980-01-17 | Novo Industri As | Proteaseprodukt mit verringerter allergener wirkung, herstellungsverfahren und waschmittel |
| US5801038A (en) * | 1984-05-29 | 1998-09-01 | Genencor International Inc. | Modified subtilisins having amino acid alterations |
| WO1992010755A1 (en) | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
| US5593877A (en) * | 1993-03-11 | 1997-01-14 | The Rockefeller University | Nucleic acid and recombinant production of vespid venom hyaluronidase |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| JPH10509324A (ja) | 1994-11-24 | 1998-09-14 | ノボ ノルディスク アクティーゼルスカブ | 抑制されたアレルゲン性を有するポリペプチドの製造のための方法 |
| US5951980A (en) * | 1995-01-06 | 1999-09-14 | Leuven Research & Development Vzw | Identification, production and use of new staphylokinase derivatives with reduced immunogenicity |
| US5837517A (en) * | 1995-05-05 | 1998-11-17 | Novo Nordisk A/S | Protease variants and compositions |
| ATE429490T1 (de) | 1995-05-05 | 2009-05-15 | Novozymes As | Protease-varianten und verbindungen |
| JP2000506119A (ja) | 1996-02-15 | 2000-05-23 | ノボ ノルディスク アクティーゼルスカブ | ポリペプチドのコンジュゲーション |
| US6300116B1 (en) | 1996-11-04 | 2001-10-09 | Novozymes A/S | Modified protease having improved autoproteolytic stability |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| AU8595298A (en) | 1997-07-29 | 1999-02-22 | The Administrators Of The Tulane Eductional Fund | Prediction, detection, and design of t cell epitopes |
| US6495136B1 (en) * | 1998-03-26 | 2002-12-17 | The Procter & Gamble Company | Proteases having modified amino acid sequences conjugated to addition moieties |
| US6835550B1 (en) | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| US6642011B2 (en) * | 1998-04-15 | 2003-11-04 | Genencor International, Inc. | Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins |
| CA2238660A1 (en) | 1998-05-22 | 1999-11-22 | Janet Chantler | Gene sequences of rubella virus associated with attenuation |
| WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
-
2000
- 2000-02-08 US US09/500,135 patent/US6838269B1/en not_active Expired - Fee Related
-
2001
- 2001-01-22 CN CN01804669A patent/CN1418253A/zh active Pending
- 2001-01-22 CA CA002399019A patent/CA2399019A1/en not_active Abandoned
- 2001-01-22 CN CNA2005100836207A patent/CN1721442A/zh active Pending
- 2001-01-22 DK DK01908667T patent/DK1254240T3/da active
- 2001-01-22 AU AU36512/01A patent/AU3651201A/en not_active Abandoned
- 2001-01-22 CN CN2010102215832A patent/CN101906464B/zh not_active Expired - Fee Related
- 2001-01-22 EP EP01908667A patent/EP1254240B1/en not_active Expired - Lifetime
- 2001-01-22 WO PCT/US2001/002204 patent/WO2001059130A2/en not_active Ceased
- 2001-01-22 DE DE60126915T patent/DE60126915T2/de not_active Expired - Lifetime
- 2001-01-22 JP JP2001558466A patent/JP5112587B2/ja not_active Expired - Fee Related
- 2001-01-22 AT AT01908667T patent/ATE355377T1/de not_active IP Right Cessation
- 2001-01-22 KR KR1020027010234A patent/KR20020073582A/ko not_active Withdrawn
- 2001-02-02 AR ARP010100505A patent/AR027358A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1418253A (zh) | 2003-05-14 |
| KR20020073582A (ko) | 2002-09-27 |
| US6838269B1 (en) | 2005-01-04 |
| JP5112587B2 (ja) | 2013-01-09 |
| EP1254240B1 (en) | 2007-02-28 |
| DK1254240T3 (da) | 2007-07-02 |
| DE60126915T2 (de) | 2007-11-15 |
| WO2001059130A2 (en) | 2001-08-16 |
| EP1254240A2 (en) | 2002-11-06 |
| ATE355377T1 (de) | 2006-03-15 |
| WO2001059130A3 (en) | 2002-03-07 |
| CN101906464B (zh) | 2013-03-27 |
| JP2004500088A (ja) | 2004-01-08 |
| CN1721442A (zh) | 2006-01-18 |
| CN101906464A (zh) | 2010-12-08 |
| AU3651201A (en) | 2001-08-20 |
| CA2399019A1 (en) | 2001-08-16 |
| DE60126915D1 (de) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR027358A1 (es) | Proteinas que producen una alteracion en la respuesta inmunogenica y metodos para fabricarlas y utilizarlas | |
| Cid et al. | Platforms for production of protein-based vaccines: from classical to next-generation strategies | |
| WO2001096368A3 (en) | Use of coiled-coil structural scaffold to generate structure-specific peptides | |
| NO20011586D0 (no) | Nye metoder for terapeutisk vaksinasjon | |
| DE69334066D1 (de) | Impfstoffzusammensetzungen für mukosale Abgabe | |
| PE20231179A1 (es) | Nuevas enzimas | |
| JP2001512748A5 (https=) | ||
| NZ710626A (en) | Pcsk9 vaccine | |
| WO2005012537A3 (en) | Adenoviral vector-based vaccines | |
| ATE457352T1 (de) | Subtilisin-carlsberg-proteine mit verminderter immunogenität | |
| NO972642D0 (no) | Fremgangsmåte for fremstilling av en proteinanalog til Bordetella-eksotoksin | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| ATE408696T1 (de) | Peptide aus dem g-protein des respiratorischen synzytialvirus und deren verwendung in einem impfstoff | |
| ATE44765T1 (de) | Lebend-impfstoff und verfahren zu dessen herstellung. | |
| ES543026A0 (es) | Un metodo para preparar una vacuna pra inducir inmunidad a la tosferina. | |
| JP2023024998A5 (https=) | ||
| DE69018926D1 (de) | Vakzine gegen Bordetella. | |
| UY23445A1 (es) | Procedimiento para la preparacion de vacunas contra la coccidiosis | |
| ATE427757T1 (de) | Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff | |
| Middlebrook | Protection strategies against botulinum toxin | |
| DE60222296D1 (de) | Impfstoff von umhüllten viren und verfahren zu seiner herstellung | |
| Mani et al. | Adjuvant Potential of Poly-α-l-Glutamine from the Cell Wall of Mycobacterium tuberculosis | |
| Viljoen et al. | Novel Developments and Next‐Generation Vaccines | |
| ATE494909T1 (de) | Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung | |
| NO20041564L (no) | Infeksios lakse anemi-virus vaksine |